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Diabetes and diabetic nephropathy are complex diseases affected by genetic and
environmental factors. Identiﬁcation of the susceptibility genes and investigation of their
roles may provide useful information for better understanding of the pathogenesis and for
developing novel therapeutic approaches. Intercellular adhesion molecule 1 (ICAM1) is a
cell surface glycoprotein expressed on endothelial cells and leukocytes in the immune
system. The ICAM1 gene is located on chromosome 19p13 within the linkage region
of diabetes. In the recent years, accumulating reports have implicated that genetic
polymorphisms in the ICAM1 gene are associated with diabetes and diabetic nephropathy.
Serum ICAM1 levels in diabetes patients and the icam1 gene expression in kidney tissues
of diabetic animals are increased compared to the controls. Therefore, ICAM1 may play a
role in the development of diabetes and diabetic nephropathy. In this review, we present
genomic structure, variation, and regulation of the ICAM1 gene, summarized genetic and
biological studies of this gene in diabetes and diabetic nephropathy and discussed about the
potential application using ICAM1 as a biomarker and target for prediction and treatment
of diabetes and diabetic nephropathy.
Keywords: intercellular adhesion molecule 1, diabetic nephropathy, end-stage renal disease, type 1 diabetes
mellitus, type 2 diabetes mellitus
INTRODUCTION
Diabetes mellitus is a group of metabolic diseases in which the
patients have high blood glucose levels. Its epidemic has become
a national and global crisis. Based upon the ﬁgures today, at
least 366 million people at the worldwide have diabetes. By the
year 2030, this number is expected to be double (Bonow and
Gheorghiade, 2004; Wild et al., 2004; Cornell and Dorsey, 2012;
Lam and LeRoith, 2012). There are two major types of dia-
betes. Type 1 diabetes (T1D), previously called juvenile diabetes
or insulin-dependent diabetes, develops on the basis of autoim-
mune destruction of pancreatic β-cells, which results in insulin
deﬁciency. It mostly affects young people (<20 years old) but
occurs also in adults (Lightfoot et al., 2012). Type 2 diabetes
(T2D) is the most common form of diabetes and accounts for
approximately 85–90% of all diabetic patients. In T2D, hyper-
glycemia results from a combination of impaired insulin secretion
and insulin resistance. When the pancreatic β-cells loose the abil-
ity to compensate for insulin resistance in liver, skeletal muscle,
and adipose tissues, hyperglycemia becomes manifest (Alberti and
Abbreviations: ACR, urinary albumin/creatinine ratio; AER, albumin excretion
rate; CD54, cluster of differentiation 54; DN,diabetic nephropathy; ESRD,end-stage
renal disease; GFR, glomerular ﬁltration rate; GoKinD, Genetics of Kidneys in Dia-
betes; HDL,high-density lipoprotein; HWE,Hardy–Weinberg equilibrium; ICAM1,
intercellular adhesion molecule 1; LD, linkage disequilibrium; LDL, low-density
lipoprotein; LFA, leukocyte adhesion protein; SNP, single-nucleotide polymor-
phism; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UTR,
un-translation region.
Zimmet, 1998). Diabetes patients often develop macro- and/or
micro-vascular complications. Diabetic nephropathy (DN) is one
of serious complications and occurs in 30–40%of diabetic patients
(Heerspink and de Zeeuw, 2011; Marshall, 2012). This diabetic
complication is characterized by pathophysiological changes in
glomerular hyperﬁltration, renal hypertrophy, tubular function
and then progress to proteinuria and reduction of glomerular
ﬁltration rate (GFR). The patients with DN exhibit persistent pro-
teinuria, hypertension, declining renal function, and increased
premature mortality largely as a result of cardiovascular disease.
DN is the most common single cause of end-stage renal disease
(ESRD). Once overt DN occurs, it progresses slowly or rapidly to
the most advanced stage of chronic kidney disease which needs
dialysis or transplantation treatment (Marshall, 2004; Shields and
Maxwell, 2010; Weil et al., 2010; Thomas and Groop, 2011). The
treatment cost for diabetes patients has been increasing stagger-
ing in the recent decades and becomes a further burden of the
healthcare system. Diabetes and DN are multi-factorial diseases,
which are inﬂuenced by both genetic and environmental factors
(Satko et al., 2005; Pitkäniemi et al., 2007; Ashcroft and Rorsman,
2012; Gonzalez-Bulnes and Ovilo, 2012; Morahan, 2012). There-
fore, identiﬁcation of the susceptibility genes in development of
diabetes and diabetic complications and investigation of their roles
are of importance to provide useful information for improvement
of the prevention and medication programs.
Intercellular adhesion molecule 1 (ICAM1, OMIM: 147840)
is a cell surface glycoprotein and expressed in endothelial cells
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and leukocytes in the immune system. This endothelial- and
leukocyte-associated transmembrane protein has been known for
its importance in stabilizing cell–cell interactions and facilitating
leukocyte endothelial transmigration. Recently, the accumulat-
ing reports from genetic studies in diabetic patients with and
without DN and from biological studies with diabetic animal
models have implicated that ICAM1 may play a role in the
pathogenesis of diabetes and DN. In this review, we will sum-
marize the genetic and pathophysiological relevance of ICAM1
and discuss about the possible role of ICAM1 in the develop-
ment of diabetes and DN as well as the perspectives of the ICAM1
research.
GENOMIC DNA STRUCTURE, mRNA AND PROTEIN OF ICAM1
The ICAM1 gene (GeneID: 3383) is located in chromosome
19p13.2 and spans 15,775 base pairs (bp) along the short arm
of this chromosome (10,381,517–10,397,291 bp from pter). Its
aliases include cluster of differentiation 54 (CD54) and cell sur-
face glycoprotein P3.58 (BB2). Figure 1 demonstrates genomic
structure, regulation, and variation of the ICAM1 gene. There are
seven exons and six introns in the ICAM1 gene. A relatively large
un-translation region (UTRs) resides respectively at both 5′ and
3′-sequences of the gene,while the translation start point is located
in exon 1. From the 2–6 exon, there is one non-synonymous single-
nucleotide polymorphism (SNP) each, by which the amino acid
changes of ICAM1 protein are caused. ICAM1 is a transmem-
brance glycoprotein molecule of the immunoglobulin superfamily
and characterized by ﬁve distinct immunoglobulin-like domains,
a transmembrance domain and a cytoplasmic tail (van de Stolpe
and van der Saag, 1996). ICAM1 protein is 505 amino acids in the
length, the molecule weights between 80 and 114 kDa depending
upon the levels of glycosylation, which varies among cell types
and environments (Newman et al., 1990). Interestingly, there are
several transcription binding proteins including NF-kappaB, NF-
kappaB1, STAT3, δCREB, STAT1, STAT1α, and STAT1β, which
may up-regulate the ICAM1 gene activity (Roebuck and Finnegan,
1999). MicroRNA (miR-221) may down-regulate the gene expres-
sion in the region of 3′-UTR of ICAM1 (Gong et al., 2011).
There are CpG islands for methylation in the promoter of the
ICAM1 gene. A study in tumor endothelial cells has demonstrated
that the ICAM1 gene activity can be epigenetically silenced by
promoter histone modiﬁcations (Hellebrekers et al., 2006). All
regulatory factors are of importance to control the ICAM1 activ-
ities in immune-related processes. Our research has been focused
on investigating whether alterations in the ICAM1 gene struc-
ture and function are associated with the development of diabetes
and DN.
LINKAGE OF THE ICAM1 GENE TO DIABETES AND DIABETIC
NEPHROPATHY
Diabetes and DN are multi-factorial diseases, which are inﬂu-
enced by both genetic and environmental factors. To search for
the susceptibility genes for the diseases, genome-wide scan linkage
analysis has been used. This is a family-based approach to inves-
tigate if the genetic markers such as microsatellites or SNPs that
span the whole genome and co-segregate with disease phenotypes.
Microsatellites are simple repeats of 1–6 bp in genome and (CA)n
is the most common form. A total of ∼30,000 microsatellites
present high levels of inter- and intra-speciﬁc polymorphisms and
distribute in whole genome (often in intergenic DNA regions and
rarely in the sequences of the genes). SNPs are the substitutions
of nucleotides in genomic DNA. In general speaking, bi-allelic
SNPs are the most common type. Tri-allelic ones and small inser-
tions/deletions are also included. C/T is the most common SNP
FIGURE 1 | Genomic DNA structure, variation, and regulation of the
ICAM1 gene.The ICAM1 gene is consisted of seven exons and six introns.
There are several non-synonymous SNPs, which reside one each in exons
2–6. In the gene promoter, there are CpG islands for methylation and
epigenetically silence by histone modiﬁcations as well as transcription binding
sites for the proteins, including NF-kappaB, NF-kappaB1, STAT3, δCREB,
STAT1, STAT1α, and STAT1β. In addition, microRNA (miR-221) in the region of
3′-UTR may down-regulate the ICAM1 gene expression.
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in the human genome. SNPs reside in the coding region of the
genes are called cSNPs, which include non-synonymous SNPs
(with amino acid changes) and synonymous SNPs (without amino
acid changes). Most of SNPs are located in non-coding regions of
the genes, including promoter, intron, and UTRs. SNPs in the
promoter region may alter transcription binding site and thereby
affect the transcriptional activity of the gene. Moreover, a number
of SNPs are found in inter-genic sequences. Up to date, more than
40 million SNPs are recorded in the public SNP databases, which
are freely available for research use. Using the genetic markers, the
linkage analysis allows us to identify the genome that is transmit-
ted within families along with the disease phenotypes of interest
at a genome-wide scale. Based on ﬁnding a statistical signal, the
probability of co-segregation of a disease with a chromosomal
locus is given (Gulcher, 2012). In this approach of genome-wide
scan, highly polymorphic genetic markers distributed across the
genome are genotyped in large family pedigrees or in affected and
discordant sibling pairs.
By using the approach of genome-wide scan and linkage anal-
yses, several chromosomal regions including 19p13 have been
predicted to linkwithdiabetes andDN.Mein et al. (1998) havepre-
viously conducted genomewide scan analysis in 93 affected sibpair
families and 263multiplex families from theUKand indicated that
loci in chromosome 19p13 are linked to T1DM. Later on, the link-
age of T1DM to chromosome 19p13 is replicated by the study with
2658 affected sib-pairs in USA (Concannon et al., 2009). Interest-
ingly, lipid-related traits such total cholesterol, triglycerides and
low-density lipoprotein (LDL) concentrations in T2DM are linked
to chromosome 19p13 and this ﬁnding has been replicated in
Caucasians, African-American and Hispanic families (Imperatore
et al., 2000; Adeyemo et al., 2005; Malhotra and Wolford, 2005).
Several interesting candidate genes, including insulin receptor,
resistin and ICAM1, are involved in the region of chromosome
19p13. The linkage of LDL concentrations to chromosome 19p13
has been replicated in the study with 612 individuals from 28
Amish families in USA (Pollin et al., 2004). Furthermore, Leon
et al. (2007) have performed a genome-wide scan study in 1251
African Americans (AA) and 1129 European Americans (EA)
hypertensive siblings from the Hypertension Genetic Epidemiol-
ogy Network study and indicated that loci in chromosome 19p are
linked with albumin to creatinine ratio (ACR) when both AA and
EA subjects are combined in the analyses. Particularly, Kathire-
san et al. (2008) have analyzed the genome-wide scan data from
three studies including 8816 T2D subjects and found six new loci
associated with LDL, cholesterol, HDL, and triglycerides. One of
the loci is located in chromosome 19p13. Previously, Arya et al.
(2006) have conducted a genome-wide scan and linkage study
and suggested that loci in both chromosomal arms of 19p13.2
and 19q13.4 may be linked to birth weight in T2D families of
both Mexican Americans and EA. By the analyses of the com-
bined metabolic syndrome and echocardiographic factors, Kraja
et al. (2008) have found the linkage of blood pressure in T2D
patients of AA and EA with the region chromosome 19p13. Tak-
ing together with the information from above brieﬂy described
genome-wide scan studies, it is clear that there are the loci in
chromosome 19p may confer the susceptibility risk to diabetes
and DN.
ASSOCIATION OF THE ICAM1 GENETIC POLYMORPHISMS
WITH DIABETES AND DIABETIC NEPHROPATHY
Several research groups including ours have reported the genetic
association studies of the ICAM1 gene in T1DM and DN. Guja
et al. (1999) reported that the transmission of the G allele of SNP
K469E (A/G) is increased in Romanian T1DM families. One year
later, Nishimura et al. (2000) replicated that this K469E poly-
morphism is associated with adult-onset T1DM in a Japanese
population. However, the association of K469E polymorphism
in the ICAM1 gene with T1DM was not found in Danish, Finnish,
and British Caucasian (Nejentsev et al., 2000). Furthermore,
Nejentsev et al. (2003) demonstrated that another synonymous
SNP G241R in the ICAM1 gene was associated with T1DM. All
these previous studies were designed for analysis of one or two
SNP(s). In order to ascertain whether the ICAM1 genetic poly-
morphisms are associated with T1DM and DN, we conducted
the comprehensive genetic association studies. The studied SNPs
including K469E and G241R were selected based upon the infor-
mation of their position in the ICAM1 gene and their linkage
disequilibrium (LD) values in the HapMap. Our data from sin-
gle marker association analyses indicated that K469E and another
intronic polymorphism (rs281432) were signiﬁcantly associated
with T1DM in Swedish Caucasians (Ma et al., 2006). Interestingly,
these two SNPs are located in intron 2 and exon 6, respectively.
According to the data of pair-wise LD values for SNPs in the
ICAM1 gene, a relatively strong LD (/D′/ ≥ 0.7) existed to extend
over the region between these two SNPs. Due to the large 5′- and
3′- UTRs in exons 1 and 7, the LD block covers almost the whole
coding region of the gene. Further multiplex marker association
analysis was done and the common haplotype C-A constructed
by C allele from K469E and A allele from rs281432 was found to
be associated with T1D (Ma et al., 2006). Later on, we found that
K469E polymorphism in the ICAM1 is associated with DN in T1D
patients of Americans of European descent and selected from the
Genetic of Kidney Diseases in Diabetes (GoKinD) study (Mueller
et al., 2006). However, no association of G241R in the ICAM1
gene with T1DM and DN in Swedish and GoKinD populations
was found (Ma et al., 2008). In patients with T2D, the K469E poly-
morphism in the ICAM1 gene was found to associate with plasma
ﬁbrinogen levels and diabetic retinopathy (Kamiuchi et al., 2002;
Yokoyama et al., 2005; Liu et al., 2006; Petrovic et al., 2008; Vinita
et al., 2012). Up to date, there is, however, no report regarding the
association of ICAM1 genetic polymorphism with DN in T2D.
Interestingly, we have observed that genotype distribution of
K469E polymorphism in the ICAM1 gene presents a high het-
erozygous index (∼50%; Ma et al., 2006). Figure 2 represents
the genotype distribution of the ICAM1 E469K polymorphism in
Swedish non-diabetic control subjects, T1D patients without and
with DN. From non-diabetic control subjects, to T1D patients
without DN and the patients with DN, the frequencies of the car-
riers with heterozygous genotype are increased, while the carriers
with 469E homozygous genotype decreased. In order to avoid the
possibility that high heterozygous index may be caused by geno-
typing errors, we conﬁrmed the genotyping experiments with two
different techniques such as dynamic allele-speciﬁc hybridization
(DASH) and pyrosequencing (Ronaghi et al., 1998; Howell et al.,
1999). In the human genome, there are segmental duplications
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FIGURE 2 | Genotype distribution of the ICAM1 K469E
polymorphism.The genotype distribution of the ICAM1 K469E
polymorphism is represented from a genetic association study in Swedish
population (Ma et al., 2006). Three genotypes of the ICAM1 K469E
polymorphism are shown in as light gray color for K469K, gray for K469E,
and dark for E469E. Obviously, the heterozygous index is high
compared to the percentage of homozygous and increased from
the group of non-diabetic control subjects, to type 1 diabetes (T1D)
patients without diabetic nephropathy and the patients with diabetic
nephropathy.
(duplicons) with >90% sequence similarity between the copies,
which may cause speciﬁc allelic and genotypic diversities, such
as high heterozygous index in complex diseases (Venter et al.,
2001; Shaw and Lupski, 2004). To ascertain whether K469E SNP
is involved in a duplicon, we further performed a cloning and
sequencing analysis and found that no duplication resides in the
gene region (Ma et al., 2006). K469E is a non-synonymous SNP in
exon 6 of the ICAM1 gene, which causes the amino acid changes
of the ICAM1 protein. We have submitted ICAM1 amino acid
sequences with K469 and 469E alleles respectively into SWISS-
MODEL (Peitsch, 1995; Arnold et al., 2006) to understand the
changes of ICAM1 protein. There are 532 amino acids in the
protein sequence of ICAM1,K469 is wild-type and has 100% iden-
tiﬁed homology. Compared to the DIMER image of wild ICAM1
protein, however, the structure of ICAM with mutant 469E is
signiﬁcantly changed. Although the modeling analysis implicates
that the K469E polymorphism in the ICAM1 gene may have func-
tional effect, further investigation with transfection of 469E allele
into cells such human embryonic kidney (HEK) 293A or with
icam1 knock-out mouse model is necessary in order to further
understand the pathogenic mechanism.
POSSIBLE ROLE OF ICAM1 IN DEVELOPMENT OF DIABETES
AND DIABETIC NEPHROPATHY
In general speaking, ICAM1 proteins act as ligands and the pri-
mary receptors for ICAM1 are integrins, which mediate cell–cell
interactions and allow signal transduction. Speciﬁcally, ICAM1,
unlike most integrin-binding proteins, does not contain an RGD
(Arg-Gly-Asp) motif to promote integrin binding (van de Stolpe
and van der Saag, 1996), but is targeted to two integrins of the
β2 subunit family, i.e., leukocyte adhesion protein-1 (LFA-1) and
Mac-1 (integrin, alpha M; Janeway, 2001). Thus, based upon
the interaction with these two molecules, ICAM1 has a role for
two important immune-related functions: T lymphocytes acti-
vation and leukocyte–endothelial cell interaction. The role of
ICAM1 in the development of diabetes and DN has not been fully
explored. Recent studies, however, have provided the information
to predict that ICAM1 is involved in the pathogenesis of diabetes
and DN (Sahakyan et al., 2010a,b).
Diabetic nephropathy is a progress disease, which is categorized
into stages based upon urinary albumin excretion (UAE) values.
The early phase, which can be reversed, is microalbuminuria. The
reduction of renal function beginswith proteinuria. Clinical inves-
tigation has demonstrated that soluble ICAM1 levels in stored
blood samples from T1D patients are higher compared to non-
diabetic control subjects. High ICAM1 levels in T1D patients are
associated with a relative risk of 1.67 (95 CI 0.96–2.92, P = 0.03)
of developing incident sustained microalbuminuria after adjust-
ment for baseline age, sex, duration of diabetes, and randomized
treatment assignment (Lin et al., 2008). Furthermore, Astrup et al.
(2008) have reported that soluble ICAM1 levels are associatedwith
all-causedmortality and cardiovascularmorbidity in T1Dpatients
withDN. The similar ﬁndings have been observed in T2Dpatients.
Soluble ICAM1 levels are signiﬁcantly correlated with albumin-
uria in T2D patients (Rubio-Guerra et al., 2007). T2D patients
with diabetic micro-angiopathic complications have higher sol-
uble ICAM1 levels in comparison with diabetic group without
micro-angiopathic complications and healthy control subjects
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(Mastej and Adamiec, 2008). The ﬁndings from clinical investiga-
tions have been supported by studies with diabetic animal models
such as the db/db mice and streptozotocin-induced rats. Com-
pared to non-diabetic rats, serum and urinary ICAM1 levels in
streptozotocin-induced rats are found to be increased, which are
parallel with the elevation of UAE (Qian et al., 2008). Furthermore,
evidence has indicated that ICAM1 is overexpressed in glomeruli
diabetic rats (Watanabe et al., 2011) and in tubular epithelial cells
of kidney in T2D db/db mice (Kosugi et al., 2009). Therefore,
ICAM1 may play a role in the development of diabetes DN and
possible mechanism is shown in Figure 3. In a diabetic condition
with hyperglycemia, the ICAM1 gene transcription in the nuclei
is increased and the ICAM1 gene expression on the surface of
endothelium cells is up-regulated. ICAM1 binding activity with
LFA-1 is increased and more lymphocytes from blood are trans-
ferred into cells in glomeruli andperitubular capillaries of nephron
in kidney. Consequently, injure of kidney glomeruli and tubular
occurs and the proteins are excreted to urine. In this ﬁgure, how-
ever, two questions still remain. First, how is ICAM1 gene activity
stimulated by high blood glucose levels? Second, how does ICAM1
elevation cause kidney tubular and glomeruli injury?
ICAM1 AS A BIOMARKERS FOR PREDICTION OF DIABETIC
NEPHROPATHY
Biomarkers are substances and structures that can be measured in
biological samples such as urine, blood, saliva, DNA, and protein.
A biomarker can be used as an indicator of a particular disease
state such as diabetes and DN (Caveney and Cohen, 2011). Cur-
rently, the biomarker used for prediction and diagnosis of DN is
UAE. This biomarker, however, is less valuable for early predic-
tion and diagnosis of DN. Therefore, researchers have searched
for novel biomarkers of DN in order to improve the diagnosis
approach and prevention program (Hellemons et al., 2012). As we
described above, genetic and biological studies have implicated
that ICAM1 plays a role in the development of diabetes and DN.
First, the ICAM1 gene is located in a linkage region with diabetes
and DN. Second, the K469E polymorphism in the ICAM1 gene
is associated with diabetes and DN. Third, serum ICAM1 levels
are gradually increased from low levels in normal albuminuria to
high levels in micro-albuminuria and to even higher levels in pro-
teinuria. Therefore, we concluded that ICAM1 is associated with
diabetes and DN. This molecule is most likely a useful biomarker
for prediction of endothelial dysfunction in diabetes and DN. Fur-
ther evaluation of ICAM1 as a biomarker in a large cohort of T1D
and T2D patients with and without DN needs to be done.
ICAM1 AS A TARGET FOR DRUG DEVELOPMENT
ICAM1 is a molecule involved in many pathways including
anti-inﬂammation. Although the picture of ICAM1 involve-
ment and interaction is complex, experiments have indicated
that inhibition of the ICAM1 gene expression may improve the
progress of diabetes andDN.Glucagon-like peptide-1 (GLP-1) has
FIGURE 3 | Possible role of ICAM1 in the development of diabetic
nephropathy. Under a diabetic condition with hyperglycemia, the
ICAM1 gene transcription in the nuclei is increased and the ICAM1
gene expression on the surface of endothelium cells is up-regulated.
ICAM1 protein binding activity with leukocyte adhesion protein-1
(LFA-1) is increased and more lymphocytes from blood are transferred
into cells of glomeruli and peritubular capillaries of nephron in kidney.
Consequently, serum ICAM1 levels are increased. Injury in kidney
glomeruli and tubular is occurred and the proteins are released to
urine.
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various extra-pancreatic actions, in addition to its enhance-
ment of insulin secretion from pancreatic islets. Kodera et al.
(2011) have demonstrated that GLP-1 receptor agonist, exendin-4,
decreases the ICAM1 gene expression and ameliorates albumin-
uria, glomerular hyperﬁltration, glomerular hypertrophy, and
mesangial matrix expansion in the diabetic rats without chang-
ing blood pressure or body weight. Furthermore, Matsui et al.
(2010) have reported that nifedipine, a calcium-channel blocker,
blocks the advanced glycation end product (AGE)-induced tubu-
lar damage and also inhibits ICAM1 gene activity in tubular
cells, which may have beneﬁts in treatment of DN. Liu et al.
(2010) have suggested that berberine can ameliorate renal dys-
function in diabetic rats by decreasing ICAM1 gene expression
and nuclear factor-kappa B (NF-kappaB) activation. Taking
together, the data from these studies suggest that ICAM1 may
be a good candidate as target for drug development. Inhibition
of ICAM1 gene activity may beneﬁt in treatment of diabetes
and DN.
SUMMARY AND PERSPECTIVES
We have described genetic and biological studies of ICAM1 in dia-
betes andDN.Data implicate that ICAM1 can be used a biomarker
for prediction of diabetes andDNandmay also be serviced as a tar-
get for drug development. To reach these two objectives, however,
we need to continuously put efforts into the study of ICAM1 in
diabetes research. First, genetic polymorphisms in the ICAM1 gene
are associatedwithT1D,T2DandDN inT1D. But, no genetic asso-
ciation with DN in T2D has been reported. Although it is known
that methylation modiﬁcation of genomic DNAs and histone pro-
teins is involved in the regulation of ICAM1 gene expression, no
epigenetic study of this gene in diabetes and DN has been done.
Second, clinical observations in diabetes patients and experimen-
tal studies with diabetic animal models have demonstrated that
elevation of serum ICAM1 levels and overexpression of the gene
in kidney tissues. Inhibition of ICAM1 gene activity with agents
may improve the kidney function, suggesting that ICAM1 may be
a target for drug development in treatment of diabetes and DN.
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